Acs Fall 2025 Vvd 130037 Vvd1300372. Acs Fall 2025 Program Cara Marris 1155 Sixteenth Street, NW, Washington, DC 20036, USA | service@acs.org | 1-800-333-9511 (US and Canada) | 614-447-3776 (outside North America) The Phase I clinical trial will evaluate the safety, pharmacokinetics and pharmacodynamics and preliminary efficacy of VVD-130037 in patients with advanced solid tumors
Acs Fall 2025 Registration Donna Konrad from donnakonrad.pages.dev
The Phase I clinical trial will evaluate the safety, pharmacokinetics and pharmacodynamics and preliminary efficacy of VVD-130037 in patients with advanced solid tumors Join us at ACS Fall 2025 in Washington, DC or online, August 17-21
Acs Fall 2025 Registration Donna Konrad
A "covalent first" chemoproteomic approach to drug discovery has enabled the discovery of small molecule activators of Kelch-like ECH associated protein 1 (KEAP1), which provide enhanced cellular degradation of the cytoprotective transcription factor nuclear factor-erythroid 2 p45-related factor 2… Choose from thousands of presentations, network, attend courses and visit the expo. The Phase I clinical trial will evaluate the safety, pharmacokinetics and pharmacodynamics and preliminary efficacy of VVD-130037 in patients with advanced solid tumors
Acs March 2025 Sybil Euphemia. Discovery of VVD-130037: A first-in-class covalent allosteric KEAP1 activator for the treatment of NRF2-activated cancers (ACS-Fall 2024) - "We will describe the identification of these molecules and the elucidation of their mechanism of action and associated structural biology Title Type Submission Type Organizer Cosponsor Description; Advances in Free Energy Methods (Invited)
Acs Fall 2025 Program Dasie Rosanne. I for advanced solid tumors from in-house chemoproteomics platform ACS Fall 2024 Meeting First-Time Disclosures Vividion Therapeutics, San Diego, CA ACS Fall 2025 Call for Abstracts; Division of Computers in Chemistry; Division of Computers in Chemistry: Call for Abstracts